We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Newborns Getting Preoperative Blood Transfusions Have More Complications

By LabMedica International staff writers
Posted on 05 Nov 2020
Blood transfusions in the neonatal patient population are common, but there are no established guidelines regarding transfusion thresholds. More...
Little is known about postoperative outcomes in neonates who receive preoperative blood transfusions (PBTs).

Transfusion practices in neonatal intensive care units (ICUs) remain highly variable despite several randomized trials showing no harm with a restrictive transfusion strategy in babies compared with a liberal one. It's not uncommon for anemic newborns to receive transfusions prior to surgery as a precaution.

Medical scientists at the Alfred I. duPont Hospital for Children (Wilmington, DE, USA) and their colleagues identified a total of 12,184 neonates, of whom 1,209 (9.9%) received a PBT, all neonates who underwent surgery. Mortality and composite morbidity (defined as any postoperative complication) in neonates who received a PBT within 48 hours of surgery were compared with that in neonates who did not receive a transfusion.

The team reported that the incidence of 30-day mortality (16.8% versus 2.6%) and morbidity (46.2% versus 16.2%) put neonates who received blood transfusion within 48 hours of surgery at a disadvantage compared with peers not getting transfusion. Blood transfusion remained associated with worse postoperative outcomes after multivariable adjustment and propensity-score matching.

Specific postoperative complications that occurred more frequently in the transfusion group included infection, bleeding requiring transfusion, reintubation, reoperation, and hospital stay beyond 30 days. However, babies who did not receive transfusion had more readmissions within 30 days of surgery. There appeared to be a stronger relationship between mortality and morbidity and blood transfusion with rising preoperative hematocrit (up to 35%), though this finding did not reach statistical significance for interaction.

The authors concluded that it is likely that there is a tipping point or range in which the risks associated with anemia outweigh the risks associated with blood transfusion. For infants with significant anemia, it is plausible that the benefits of a blood transfusion, such as increased oxygen delivery, outweigh the associated risks (i.e., transfusion-related immunomodulation and a proinflammatory state), but as the anemia becomes less severe, the harm of a blood transfusion begins to outweigh the benefit. The study was published on October 1, 2020 in the journal Pediatrics.

Related Links:
Alfred I. duPont Hospital for Children


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Platelet Function Analyzer
PL-12
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.